Teva Receives Final Approval For Generic Prevacid(R) Delayed-Release Capsules
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company’s Abbreviated New Drug Application (ANDA) to market its generic version of Tap Pharmaceutical’s proton pump inhibitor Prevacid® (lansoprazole) Delayed-Release Capsules, 15 mg and 30 mg.
See original here:
Teva Receives Final Approval For Generic Prevacid(R) Delayed-Release Capsules
Related posts:
- Impax Laboratories Confirms Patent Challenge Relating To ORACEA(R) Delayed-Release Capsules, 40mg
- APP Pharmaceuticals Receives Approval For The First Generic Chlorothiazide Sodium For Injection, USP
- APP Pharmaceuticals Receives Approval For Deferoxamine Mesylate For Injection, USP
- Shire Announces FDA Approval Of Once-Daily INTUNIV™ Extended Release Tablets For The Treatment Of ADHD In Children And Adolescents Aged 6 To 17
- Mylan’s Matrix Receives Tentative FDA Approval Under PEPFAR For Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate Tablets